Cancer Family
Embryonal Neoplasm
CI-CAN-00000013Explore in graph →
Non-malignant285 active trials7 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000013Explore in graph →
Clinical trials
1,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04724369 | Open-Label Study of 18F-mFBG for Imaging Neuroblastoma | completed | Phase 3 | 43 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01445288 | Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | completed | — | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 |
| clinicaltrials |
| NCT02040376 | Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma | completed | Phase 3 | 24 | The Hospital for Sick ChildrenOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04868799 | Finding New Targets by Proteomic Approaches (InnovRT1)(InnovRT1) | completed | — | 44 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT01857934 | Therapy for Children With Advanced Stage Neuroblastoma | completed | Phase 2 | 153 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03251989 | Rare CNS Tumors Outcomes &Risk | completed | — | 326 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833631 | A Prospective Image Reevaluation Study to Assess the Efficacy of 18F-mFBG PET Imaging in Subjects With Neuroblastoma(101-305) | completed | — | 43 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05027386 | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. | completed | Phase 1 / Phase 2 | 125 | Sun Yat-sen UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT01875601 | NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | completed | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT01946529 | Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors | completed | Phase 2 | 24 | St. Jude Children's Research HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05395741 | Regorafenib in Patients With Refractory Primary Bone Tumors(Regbone) | completed | Phase 1 / Phase 2 | 30 | Institute of Mother and Child, Warsaw, PolandOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT00918320 | Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours(TOTEM2) | completed | Phase 2 | 129 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT00407433 | Clinical Studies of Gemcitabine-Oxaliplatin | completed | Phase 2 | 156 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT01326104 | Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor(Re-MATCH) | completed | Phase 2 | 26 | University of FloridaOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | completed | Phase 1 | 32 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 13, 2026 | clinicaltrials |
| NCT00911560 | Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma | completed | Phase 1 / Phase 2 | 374 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06822842 | Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models | completed | — | 1,229 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT00379340 | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor | completed | Phase 3 | 395 | Children's Oncology GroupNETWORK | 7 | Jul 24, 2026 | clinicaltrials |
| NCT02389244 | A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas(REGOBONE) | completed | Phase 2 | 163 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT00904241 | Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma | completed | — | 10,000 | Children's Oncology GroupNETWORK | 8 | Jul 9, 2026 | clinicaltrials |
| NCT00980460 | Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | completed | Phase 3 | 236 | National Cancer Institute (NCI)NIH | 6 | Jun 30, 2026 | clinicaltrials |
| NCT04168788 | Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL(MVO) | completed | N/A | 85 | University Hospital, AngersOTHER_GOV | 1 | Jun 29, 2026 | clinicaltrials |
| NCT00085735 | Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma | completed | Phase 3 | 549 | Children's Oncology GroupNETWORK | 7 | Jun 9, 2026 | clinicaltrials |
| NCT00392327 | Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET | completed | Phase 3 | 379 | Children's Oncology GroupNETWORK | 5 | Jun 8, 2026 | clinicaltrials |
| NCT00352534 | Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor | completed | Phase 3 | 808 | Children's Oncology GroupNETWORK | 7 | Jun 3, 2026 | clinicaltrials |
| NCT00945009 | Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor | completed | Phase 3 | 249 | Children's Oncology GroupNETWORK | 6 | Jun 3, 2026 | clinicaltrials |
| NCT03786783 | Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 3 | Jun 2, 2026 | clinicaltrials |
| NCT00898365 | Study of Kidney Tumors in Younger Patients | completed | — | 8,000 | Children's Oncology GroupNETWORK | 7 | May 18, 2026 | clinicaltrials |
| NCT02308527 | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children(BEACON) | completed | Phase 2 | 225 | University of BirminghamOTHER | 10 | May 12, 2026 | clinicaltrials |
| NCT03966651 | A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.(NEUROBLU 02) | completed | Phase 1 | 1 | Institut Claudius RegaudOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT00253435 | N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma | completed | Phase 2 | 50 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Apr 28, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT00083135 | N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation | completed | Phase 1 | 18 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT00093353 | N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma | completed | Phase 1 | 30 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT00295919 | N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma | completed | Phase 1 | 80 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT00509353 | N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma | completed | Phase 1 | 26 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT00646230 | N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma(IV Fenretinide) | completed | Phase 1 | 17 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Apr 14, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT02945800 | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | completed | Phase 2 | 59 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05046314 | A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma | completed | Phase 2 | 15 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT00026312 | Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | completed | Phase 3 | 1,449 | National Cancer Institute (NCI)NIH | 5 | Mar 5, 2026 | clinicaltrials |
| NCT02909777 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03361033 | Components of Social Functioning in Survivors of Pediatric Brain Tumors | completed | — | 80 | St. Jude Children's Research HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02415816 | Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas | completed | N/A | 98 | St. Jude Children's Research HospitalOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT00336024 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma | completed | Phase 3 | 91 | Children's Oncology GroupNETWORK | 4 | Jan 23, 2026 | clinicaltrials |
| NCT01175356 | Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | completed | Phase 1 | 99 | Children's Oncology GroupNETWORK | 1 | Jan 23, 2026 | clinicaltrials |
| NCT01231906 | Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma | completed | Phase 3 | 642 | Children's Oncology GroupNETWORK | 6 | Jan 23, 2026 | clinicaltrials |
| NCT00085930 | Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients(NESTLES) | completed | Phase 1 | 19 | Baylor College of MedicineOTHER | 1 | Jan 7, 2026 | clinicaltrials |
Data updated 9 hours agoSource updated Sep 29, 2026source: clinicaltrials